Teva-Xenon painkiller wins orphan designation from FDA

04/24/2013 | Pharmaceutical Business Review Online

The FDA has granted orphan-drug status to Teva Pharmaceutical and Xenon Pharmaceuticals' XEN402, an experimental drug for pain associated with erythromelalgia. A midstage trial showed that the drug, which inhibits the SCN9A sodium channel, alleviates erythromelalgia-related pain.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI